Evidence map›Paper›PMID 41835003›Full record

ArticleFrontiers in cellular and infection microbiology2026

The

Xiaosi Li, Yan Feng, Xiaoyan Wu, Heping Shen, Shumi Shang, Wenting Tang, Fupin Hu, Huijun Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaosi Li *Department of Laboratory Medicine, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Yan Feng *Department of Laboratory Medicine, Jiaxing Maternity and Child Health Care Hospital, College of Medicine, Jiaxing University, Jiaxing, China.
Xiaoyan WuDepartment of Laboratory Medicine, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Heping ShenDepartment of Infectious Disease, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Shumi ShangDepartment of Laboratory Medicine, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Wenting TangDepartment of Laboratory Medicine, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Fupin HuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Huijun LiangDepartment of Laboratory Medicine, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ceftazidime-avibactam represents a crucial therapeutic option for managing infections attributable to carbapenem-resistant Methods: The susceptibility testing was performed using the broth microdilution method, conjugation experiment was performed via the filter mating method, the genetic surroundings of Results: For Discussion: These mobile genetic elements may play a role in the capture and dissemination of the

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug Resistance, Multiple, BacterialPseudomonas aeruginosaDrug CombinationsHumansMicrobial Sensitivity TestsPlasmidsPseudomonas InfectionsThird Generation CephalosporinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug CombinationsThird Generation CephalosporinsblaKPC-249Ceftazidime-avibactamP. aeruginosaresistanceST463

Identifiers

PMID41835003
PMCPMC12982449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.